Serum samples were used to perform the following measurements, through automatic validated methods and equipment (Hitachi 717 analyzer, Roche Diagnostics GMBH, Mannheim, Germany), as previously described [50 (link)]: postprandial glucose, triglycerides (TGs), total-cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels, as well as serum glutamic-oxaloacetic (GOT) and glutamic-pyruvic (GPT) transaminases concentrations. Hemoglobin A1c (HbA1c) levels were determined using the DCA 2000+ analyzer (Bayer Diagnostics, Barcelona, Spain), according to the manufacturer’ instructions. Serum insulin levels were determined by Enzyme-Linked ImmunoSorbent Assay (ELISA) using commercially available kits for rat samples from Mercodia (Uppsala, Sweden). Insulin resistance was evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR) index, which was calculated as previously described [51 (link)], using the following formula: HOMA-IR index = [fasting glucose (mmol/L) × fasting insulin (µU/L)]/22.5. High-sensitivity C-reactive protein (hs-CRP) was assayed by using a rat-specific Elisa kit (MBS764381 from Mybiosource, San Diego, CA, USA) according to the manufacturer’ instructions.
Free full text: Click here